Paraoksonaz-1 Enzimi ve Koroner Kalp Hastalıkları ile İlişkisi

Yıl 2011, Cilt: 24 Sayı: 1, 59 - 63, 21.04.2015

Özlem Tarçın

Öz

Anti-oksidan bir enzim olan paraoksonaz-1(PON1) enzim düzeyi ve aktivitesi, koroner arter hastalığı ile ilişkili olan hipertansiyon, diyabet, hiperlipidemi ve sigara kullanımı ile azalmaktadır. Tüm çalışmalar anjiografik olarak koroner arter hastalığı(KAH) kanıtlanmış olan hastalarda PON1 düzeyinin düştüğünü göstermektedir. Ancak polimorfizm açısından net olarak tek bir polimorfizm ile ilişkisi gösterilememiştir. Bu bilgilerin ışığında PON1 enzim düzeyi, KAH gelişimi açısından belirleyici bir marker olabilir. Ancak bunun klinik olarak kanıtlanması için prospektif ve kontrollü çalışmalara ihtiyaç vardır.

Anahtar Kelimeler: Paraoksonaz-1, Koroner kalp hastalıkları, PON1 polimorfizm

Anahtar Kelimeler

-

Kaynakça

• Primo-Parmo SL, Sorenson RC, Teiber J, La Du
• BN. The human serum paraoxonase/arylesterase
• gene (PON1) is one member of a multigene family.
• Genomics 1996;33:498-507. doi:
• 1006/geno.1996.0225
• Mackness MI, Hallam SD, Peard T, Warner S,
• Walker CH. The separation of sheep and human
• serum “A”-esterase activity into the lipoprotein
• fraction by ultracentrifugation. Comp Biochem
• Physiol B 1985;82:675-677.
• Reddy ST, Wadleigh DJ, Grijalva V, et al. Human
• paraoxonase-3 is an HDL-associated enzyme with
• biological activity similar to paraoxonase-1 protein
• but is not regulated by oxidized lipids. Arterioscler
• Thromb Vasc Biol 2001;21:542-547.
• Mochizuki H, Scherer SW, Xi T,et al. Human PON2
• gene at 7q21.3:cloning, multiple mRNA forms, and
• missense polymorphisms in the coding sequence.
• Gene 1998;213:149-157. doi: 10.1016/S0378-
• (98)00193-0
• Costa LG, Vitalone A, Cole TB, et al. Modulation of
• paraoxonase (PON1) activity. Biochem Pharmacol
• ;69: 541-550. doi: 10.1016/j.bcp.22004.08.027
• Mueller RF, Hornung S, Furlong CE, Anderson J,
• Giblett ER, Motulsky AG. Plasma paraoxonase
• polymorphism: a new enzyme assay, population,
• family, biochemical and linkage studies. Am J Hum
• Genet 1983;35:393-408.
• Cole TB, Jampsa RL, Walter BJ, Arndt TL, Richter
• RJ, Shih DM, et al. Expression of human
• paraoxonase (PON1) during development.
• Pharmacogenetics 2003;13:1-8. do.:
• 1097/00008571-200306000-00007
• Augustinsson KB, Barr M. Age variation in plasma
• arylesterase activity in children. Clin Chim Acta
• ;8:568-573. doi: 10.1016/0009-8981(63)90106-
• -
• Ecobichon DJ, Stephens DS. Perinatal
• development of human blood esterases. Clin
• Pharmacol Ther 1973;14:41-47.
• de Roos NM, Schouten EG, Scheek LM, van Tol A,
• Katan MB. Replacement of dietary saturated fat
• with trans fat reduces serum paraoxonase activity in
• healthy men and women. Metabolism
• ;51:1534-1537. doi: 10.1053/meta.2002.36305
• Wallace AJ, Sutherland WHF, Mann JI, Williams
• SM. The effect of meals rich in thermally stressed
• olive and safflower oils on post-prandial serum
• paraoxonase activity in patients with diabetes. Eur J
• Clin Nutr 2001;55:951-958.
• Deakin SP, James RW. Genetic and enviromental
• factors modulating serum concentrations and
• activities of the antioxidant enzyme paraoxonase-1.
• Clinical Science 2004;107: 435-447. doi:
• 1042/CS20040187
• Mackness MI, Arrol S, Durrington PN. Paraoxonase
• prevents accumulation of lipoperoxides in lowdensity
• lipoprotein. FEBS Lett. 1991;286(1-2):152-
• doi: 10.1016//0014-5793(91)80962-3
• Gordon T, Castelli WP, Hjortland MC, Kannel WB,
• Dawber TR. High density lipoprotein as a protective
• factor against coronary heart disease. The
• Framingham Study. Am J Med 1977;62:707-714.
• doi: 10.1016/00029343(77)90874-9
• Kaysen GA. Potential restoration of HDL function
• with apolipoprotein A-I mimetic peptide in end-stage
• renal disease. Kidney Int 2009;76(4):359-61. doi:
• 1038/ki.2009.205
• Mackness B, Hine D, Liu Y, et al. Paraoxonase-1
• inhibits oxidized LDL-induced MCP-1 production by
• endothelial cells. Biochem Biophys Res Commun
• ;318:680-683. doi: 10.1016/j.bbrc.2004.04.056
• Ferretti G, Bacchetti T, Marchionni C,et al. Effect of
• glycation of high density lipoproteins on their
• physiochemical properties and on paraoxonase
• activity. Acta Diabetol 2001;38:163-169. doi:
• 1007/s592-001-8074-z
• Gofman JW, Young W, Tandy R. Ischemic heart
• disease, atherosclerosis, and longevity. Circulation
• ;34:679-697.
• Rozenberg O, Rosenblat M, Coelman R, et al.
• Paraoxonase (PON1) deficiency is associated with
• increased macrophage oxidative stres: studies in
• PON1-knockout mice. Free Radic Biol Med
• ;34:774-784. doi: 10.1016/S0891-
• (02)01429-6
• Navab M, Hama-Levy S, Van Lenten BJ, Fonarow
• GC, Carlinez CJ, Castellani LW. Mildly oxidised
• LDL induces an increased apolipoprotein
• J/paraoxonase ratio. J Clin Invest 1997;99:2005-
• doi: 10.1172/JCI119369
• Singh S, Venkatesh S, Verma JS, Verma M,
• Lellama CO, Goel RC. Paraoxonase(PON1) activity
• in North west Indian Punjabis with coronary artery
• disease. Indian J Med Res 2007;125:783-787.
• Jayakumari N, Thejaseebai G. High prevalence of
• low serum paraoxonase1 in subjects with coronary
• artery disease. J Clin Biochem Nutr 2009;45(3):278-
• doi: 10.3164/jcbn.08-255
• Kabaroğlu C, Mutaf I, Boydak B, et al. Association
• between serum paraoxonase activity and oxidative
• stress in acute coronary syndromes. Acta Cardiol
• ;59:606-611.
• Aviram M, Rosenbalt M. Paraoxonases and
• cardiovascular diseases: pharmacological and
• nutritional influences. Curr Opin Lipidol
• ;16:393-399.
• Suehiro T, Nakanchi Y, Yammamoto M, Arii K, Itoh
• H, Hamashige N, et al. Paraoxonase gene
• polymorphism in Japanese subjects with coronary
• heart disease. Br J Pharmacol 1996;57:69-73. doi:
• 1016/S0167-5273(96)02779-9
• Antikainen M, Mutomaki S, Syvanne M, Pahlman R,
• Tanvanainen E, Jauhianen M, et al. The Gln Arg
• polymorphism of human paraoxonase gene
• (HUMPONA) is not associated with the risk of
• coronary artery disease in Finns. J Clin Invest
• ;98:883-885.
• Mukamal KJ, Pai JK, Jensen MK, Rimm EB.
• Paraoxonase 1 polymorphisms and risk of
• myocardial infarction in women and men. Circ J
• ;73(7):1302-1307. doi: 10.1253/circj.CJ-08-
• -
• Rios DL, D’Onofrio LO, Cerqueira CC, Bonfim-Silva
• R, Carvalho HG, Santos-Filho A, et al. Paraoxonase
• gene polymorphisms in angiographically
• assessed coronary artery disease: evidence for
• gender interaction among Brazilians. Clin Chem
• Lab Med 2007;45:874-878. doi:
• 1515/CCLM.2007.136
• Sanghera DK, Saha N, Aston CE, Kamboh MI.
• Genetic polymorphism of paraoxonase and the risk
• of coronary heart disease. Arterioscler Thromb
• Vasc Biol 1997;17:1067-1073.
• Ruiz J, Blanche H, James RW, Garin MC, Vaisse C,
• CharpentierG, Cohen N, Morabia A, Passa P,
• Froguel P. Gln-Arg 192 polymorphism of
• Ö. TARÇIN
• Paraoksonaz-1 ve koroner kalp hastalığı
• Marmara Medical Journal 2011; 24 (1):59-63
• -
• paraoxonase and coronary heart disease in type 2
• diabetes. Lancet 1995;346(8979):869-872.
• doi:10.1016/S0140-6736(95)92709-3
• Kaman D, İlhan N, Metin K, Akbulut M, Üstündağ B.
• A preliminary study of human paraoxonase and
• PON1 L/M55-PON1 Q/R192 polymorphisms in
• Turkish patients with coronary artery disease. Cell
• Biochem Funct 2009;27:88-92. doi:
• 1002/cbf.1539
• Özkök E, Aydın M, Babalık E, Özbek Z, İnce N,
• Kara İ. Combined impact of matrix
• metalloproteinase-3 and paraoxonase 1 55/192
• gene variants on coronary artery disease in Turkish
• Patients. Med Sci Monit 2008;14(19):536-542.
• Aynacıoğlu AS, Kepekçi Y. The human
• paraoxonase Gln-Arg 192(Q/R) polymorphism in
• Turkish patients with coronary artery disease. Int J
• Cardiol 2000;12:33-37. doi: 10.1016.S0167-
• (00)00242-4
• Wheeler JG, Keavney BD, Watkins H, Collins R,
• Danesh J. Four paraoxonase gene polymorphism in
• cases of coronary heart diseases and 12786
• controls: meta-analysis of 43 studies. Lancet
• ;363(9410):689-695. doi: 10.1016/S0140-
• (04)15642-0
• Tartan Z, Orhan G, Kaşıkçıoğlu H, Uyarel H, Ünal
• S, Özer N, Özay B, Çiloğlu F, Çam N. The role of
• paraoxonase (PON) enzyme in the extent and
• severity of the coronary artery disease in type-2
• diabetic patients. Heart Vessels 2007;22(3):158-
• doi: 10.1007/s00380-0060957-6
• Ferretti G, Bacchetti T, Busni D, et al. Protective
• effect of paraoxonase activity in high-density
• lipoproteins against erythrocyte membranes
• peroxidation: a comparison between healthy
• subjects and type 1 diabetic patients. J Clin
• Endocrinol Metab 2004;89:2957-2962.
• Karabina SA, Lehner AN, Franke E, Parthasara S,
• Santanam N. Oxidative inactivation of paraoxonaseimplications
• in diabetes mellitus and
• atherosclerosis. Biochim Biophys Acta
• ;1725(2):213-221. doi:
• 1016/j.bbagen.2005.07.005
• Flekac M, Skrha J, Zidkova K, Lacinova Z,
• Hilgertova J. Paraoxonase 1 gene polymorphisms
• and enzyme activities in diabetes mellitus. Physiol
• Res 2008;57(5):717-26.
• Chen X, Wu Y, Liu L, Su Y, Peng Y, Jiang L, Liu X,
• Huang D. Relationship between high density
• lipoprotein antioxidant activity and carotid intima
• media thickness in patients with essential
• hypertension. Clin Exp Hypertens 2010;32:13-20.
• Yıldız A, Gür M, Demirbağ R, Yılmaz R, Akyol S,
• Aslan M, Erel O. Paraoxonase and arylesterase
• activities in untreated dipper and non-dipper
• hypertensive patients. Clin Biochem 2008;41(10-
• :779-784. doi:
• 1016/j.clinbiochem.2008.02.010
• Ohkubo T, Imai Y, Tsuji I, Nagai K, Watanabe N,
• Minami N, et al. Relation between nocturnal decline
• in blood pressure and mortality. The Ohasama
• Study. Am J Hypertens 1997;10:1201-1207. doi:
• 1016/S0895-7061(97)00274-4
• Metohi H, Ohkubo T, Kikuya M, Asayama K, Obara
• T, Hashimoto J, et al. Prognostic significance for
• stroke of a morning pressor surge and a nocturnal
• blood pressure decline:the Ohasama study.
• Hypertension 2006;47:149-154. doi:
• 1161/01.HYP.0000198541.12640.0f
• Connelly PW, Zinman B, Maguire GF,
• Mamakeesick M, Haris SB, Hegele RA, Retnakaren
• R, hanley AJ. Association of the novel
• cardiovascular risk factors paraoxonase 1 and
• cystatin C in type 2 diabetes. J Lipid res
• ;50(6):1216-1222. doi: 10.1194/jlr.P80070-
• JLR200
• Ribas V, Sanchez-Quesada JL, Anton R, Camacho
• M, Julve J, Escola-Gil JC, Vila L, Ordonez-Llanos J,
• Blanco-Vaca F. Human apolipoprotein A-II
• enrichement displaces paraoxonase from HDL and
• impairs its antioxidant properties. Circ Res
• ;95:789-797. doi:
• 1161/01.RES0000146031.94850.5f
• Paragh G, Seres I, Harangi M, Balogh Z, Illyes L, et
• al. The effect of micronised fenofibrate on
• paraoxonase activity in patients with coronary heart
• disease. Diabetes Metab 2003;29:613-618. doi:
• 1016/S1262-3636(07)70077-0
• Beltowski J, Wòjcicka G, Mydlarczyk M, Jamroz A.
• The effect of peroxisome proliferator-activated
• receptors (PPAR) alpha agonist, fenofibrate, on lipid
• peroxidation, total antioxidant capacity, and
• plasma paraoxonase 1(PON1) activity. J Physiol
• Pharmacol 2002;53:463-475.
• Balogh Z, Seres I, Harangi M, Kovacs P, Kakuk Gy,
• Paragh Gy. Gemfibrozil increases paraoxonase
• activity in type 2 diabetic patients. A new hypothesis
• of the beneficial action of fibrates? Diabetes Metab
• ;27:604-610.
• Durrington PN, Mackness MI, Bhatnagar D, Julier
• K, Prais H, Arrol S, Morgan J, Wood GNI. Effects of
• two different fibric acid derivatives on lipoproteins,
• cholesterol ester transfer, fibrinogen, plasminogen
• activator inhibitor and paraoxonase activity in type
• IIb hyperlipoproteinemia. Atherosclerosis
• ;138:217-225. doi:
• 1161/01.ATV.0000027414.34728.1F
• Senti M, Tomas M, Anglada R, Elosua R, Marrugat
• J, Covas MI, et al. Inter-relationship of smoking,
• paraoxonase activity, and leisure time physical
• activity:a population based study. Eur J Int Med
• ;14:178-184. doi: 10.10167S0953-
• (03)00041-4
• Mouhamed DH, Ezzaher A, Araoud M, Neffati F,
• Douki W, Najjar MF. Paraoxonase 1(PON1) activity
• and lipid parameters in Tunusian smokers. Ann Biol
• Clin 2010;68;143-147. doi: 10.1684/abc.2010.0418
• James RW, Leviev I, Righetti A. Smoking is
• associated with reduced serum paraoxonase
• activity and concentration in patients with coronary
• artery disease. Circulation 2000;101:2252-2257.
• Nishio E, Watanabe Y. Cigarette smoke extracts
• inhibits plasma paraoxonase activity by modification
• of the enzyme’s free thiols. Biochem Biophys Res
• Comm 1997;236:289-293. doi:
• 1006/bbrc.1997.6961